These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. AMD3465, a monomacrocyclic CXCR4 antagonist and potent HIV entry inhibitor. Hatse S; Princen K; De Clercq E; Rosenkilde MM; Schwartz TW; Hernandez-Abad PE; Skerlj RT; Bridger GJ; Schols D Biochem Pharmacol; 2005 Sep; 70(5):752-61. PubMed ID: 16011832 [TBL] [Abstract][Full Text] [Related]
5. Different stereochemical requirements for CXCR4 binding and signaling functions as revealed by an anti-HIV, D-amino acid-containing SMM-chemokine ligand. Dong CZ; Kumar S; Choi WT; Madani N; Tian S; An J; Sodroski JG; Huang Z J Med Chem; 2005 Dec; 48(25):7923-4. PubMed ID: 16335916 [TBL] [Abstract][Full Text] [Related]
6. Synthesis and structure-activity relationships of azamacrocyclic C-X-C chemokine receptor 4 antagonists: analogues containing a single azamacrocyclic ring are potent inhibitors of T-cell tropic (X4) HIV-1 replication. Bridger GJ; Skerlj RT; Hernandez-Abad PE; Bogucki DE; Wang Z; Zhou Y; Nan S; Boehringer EM; Wilson T; Crawford J; Metz M; Hatse S; Princen K; De Clercq E; Schols D J Med Chem; 2010 Feb; 53(3):1250-60. PubMed ID: 20043638 [TBL] [Abstract][Full Text] [Related]
7. Computer-based design of novel HIV-1 entry inhibitors: neomycin conjugated to arginine peptides at two specific sites. Berchanski A; Lapidot A J Mol Model; 2009 Mar; 15(3):281-94. PubMed ID: 19057930 [TBL] [Abstract][Full Text] [Related]
8. Peptide-lead CXCR4 antagonists with high anti-HIV activity. Fujii N; Tamamura H Curr Opin Investig Drugs; 2001 Sep; 2(9):1198-202. PubMed ID: 11717804 [TBL] [Abstract][Full Text] [Related]
9. Anti-HIV activity and conformational studies of peptides derived from the C-terminal sequence of SDF-1. Dettin M; Pasquato A; Scarinci C; Zanchetta M; De Rossi A; Di Bello C J Med Chem; 2004 Jun; 47(12):3058-64. PubMed ID: 15163187 [TBL] [Abstract][Full Text] [Related]
10. Bacterial RNase P RNA is a drug target for aminoglycoside-arginine conjugates. Berchanski A; Lapidot A Bioconjug Chem; 2008 Sep; 19(9):1896-906. PubMed ID: 18712898 [TBL] [Abstract][Full Text] [Related]
11. Anti-human immunodeficiency virus activity of novel aminoglycoside-arginine conjugates at early stages of infection. Cabrera C; Gutiérrez A; Blanco J; Barretina J; Litovchick A; Lapidot A; Evdokimov AG; Clotet B; Esté JA AIDS Res Hum Retroviruses; 2000 May; 16(7):627-34. PubMed ID: 10791873 [TBL] [Abstract][Full Text] [Related]
14. Unique ligand binding sites on CXCR4 probed by a chemical biology approach: implications for the design of selective human immunodeficiency virus type 1 inhibitors. Choi WT; Tian S; Dong CZ; Kumar S; Liu D; Madani N; An J; Sodroski JG; Huang Z J Virol; 2005 Dec; 79(24):15398-404. PubMed ID: 16306611 [TBL] [Abstract][Full Text] [Related]
15. The role of positively charged residues in CXCR4 recognition probed with synthetic peptides. Luo Z; Zhou N; Luo J; Hall JW; Huang Z Biochem Biophys Res Commun; 1999 Oct; 263(3):691-5. PubMed ID: 10512741 [TBL] [Abstract][Full Text] [Related]
16. Identification of a D-amino acid decapeptide HIV-1 entry inhibitor. Boggiano C; Jiang S; Lu H; Zhao Q; Liu S; Binley J; Blondelle SE Biochem Biophys Res Commun; 2006 Sep; 347(4):909-15. PubMed ID: 16854380 [TBL] [Abstract][Full Text] [Related]
17. Structure-activity relationships of aminoglycoside-arginine conjugates that bind HIV-1 RNAs as determined by fluorescence and NMR spectroscopy. Lapidot A; Vijayabaskar V; Litovchick A; Yu J; James TL FEBS Lett; 2004 Nov; 577(3):415-21. PubMed ID: 15556620 [TBL] [Abstract][Full Text] [Related]
18. Rev-derived peptides inhibit HIV-1 replication by antagonism of Rev and a co-receptor, CXCR4. Shimane K; Kodama EN; Nakase I; Futaki S; Sakurai Y; Sakagami Y; Li X; Hattori T; Sarafianos SG; Matsuoka M Int J Biochem Cell Biol; 2010 Sep; 42(9):1482-8. PubMed ID: 20580677 [TBL] [Abstract][Full Text] [Related]